著者

橋本 貞夫 鈴江 崇志

出版者

The Society of Synthetic Organic Chemistry, Japan

雑誌

有機合成化学協会誌 (ISSN:00379980)

巻号頁・発行日

vol.38, no.6, pp.528-537, 1980-06-01 (Released:2009-11-13)

参考文献数

33

被引用文献数

1 2

---

1- (Tetrahydro-2-furanyl) -5-fluorouracil (Futraful®, FT-207) was synthesized by S.A. Hiller, et al. in 1967. In this 5-fluorouracil (5-FU) derivative, a tetrahydrofuran group replace the sugar on the nucleoside.FT-207 is an antimetabolite, anti-tumor agent, and is well absorbed from the intenstine. It is gradually metabolized to substances such as 5-FU, 5-fluorouridine (FUR) and 5-Fluorouridine monophosphate (FUMP), which exhibit anti-tumor activity. These active substances are maintained in the blood and tissues for a long time, and thus FT-207 shows significant anti-tumor activity.FT-207 has less effect than other anti-tumor agents on antibody production, the blood picture and the functions of the liver, spleen and kidney. Thus since it has only side effects, it can be used for a long-term therapeutic treatment.It is effective when given intravenously, orally or intrarectally and has been employed clinically to induce tumor regression and to maintain regression and inhibit metastases.

著者

荒川 忠良 藤本 昌久 鈴江 崇志 米本 陸正

出版者

日本皮膚科学会西部支部

雑誌

西日本皮膚科 (ISSN:03869784)

巻号頁・発行日

vol.32, no.1, pp.73-75, 1970-02-01 (Released:2012-03-26)

参考文献数

4

著者

鈴江 崇志 丸中 照義

出版者

日本化学会

雑誌

化学と工業 (ISSN:00227684)

巻号頁・発行日

vol.29, no.9, pp.p742-745, 1976-09

著者

安田 行寛 東郷 常夫 采見 憲男 渡辺 昭治 播磨 耕介 鈴江 崇志

出版者

公益社団法人 日本化学療法学会

雑誌

CHEMOTHERAPY (ISSN:00093165)

巻号頁・発行日

vol.21, no.6, pp.1171-1178, 1973-08-25 (Released:2011-03-08)

参考文献数

9

被引用文献数

1

---

N1-(2-Tetrahydrofuryl)-5-fluorouracil (FT-207), a new antimetabolic anticancer agent synthesized in USSR, was studied on antimicrobial activity in vitro and distribution, excretion and metabolism in vivo.The results obtained were as follows.1) Antimicrobial activityFT-207 showed fairly active against Micrococcus flavus ATCC 10240, Sarcina lutea PCI 1001, Staphylococcus epidermidis and Staphylococcus aureus 209 P, but in general the activity was inferior to that of 5-FU.2) DistributionBy the intravenous administration of FT-207, 400mg/kg, in normal and AH-130 bearing rats, the concentration of FT-207 in serum and tissues maintained measurably until 16-24 hours.On the other hand, the active substances (5-FU, etc.) from FT-207 detected at 1-4 hours and peaked at 4-16 hours in tissues.3) Urinary excretionFT-207 and its active substances were excreted in urine for a long time, and the recoveries of FT-207 for 48 hours in rats, mice and rabbits were 12-18%.4) MetabolismIn normal and AH-130 bearing rats, the main active substance from FT-207 administrated intravenously was 5-FU.

著者

安田 行寛 東郷 常夫 采見 憲男 渡辺 昭治 播磨 耕介 鈴江 崇志

出版者

公益社団法人 日本化学療法学会

雑誌

日本化学療法学会雑誌 (ISSN:00093165)

巻号頁・発行日

vol.21, no.6, pp.1171-1178, 1973

---

N<SUB>1</SUB>-(2-Tetrahydrofuryl)-5-fluorouracil (FT-207), a new antimetabolic anticancer agent synthesized in USSR, was studied on antimicrobial activity <I>in vitro</I> and distribution, excretion and metabolism <I>in vivo</I>.<BR>The results obtained were as follows.<BR>1) Antimicrobial activity<BR>FT-207 showed fairly active against <I>Micrococcus flavus</I> ATCC 10240, <I>Sarcina lutea</I> PCI 1001, <I>Staphylococcus epidermidis</I> and <I>Staphylococcus aureus</I> 209 P, but in general the activity was inferior to that of 5-FU.<BR>2) Distribution<BR>By the intravenous administration of FT-207, 400mg/kg, in normal and AH-130 bearing rats, the concentration of FT-207 in serum and tissues maintained measurably until 16-24 hours.<BR>On the other hand, the active substances (5-FU, <I>etc</I>.) from FT-207 detected at 1-4 hours and peaked at 4-16 hours in tissues.<BR>3) Urinary excretion<BR>FT-207 and its active substances were excreted in urine for a long time, and the recoveries of FT-207 for 48 hours in rats, mice and rabbits were 12-18%.<BR>4) Metabolism<BR>In normal and AH-130 bearing rats, the main active substance from FT-207 administrated intravenously was 5-FU.